Fearing Second Offer Failure, Stada Management Appeals To Shareholders

Stada's management is scared an offer from two private-equity suitors will fail a second time due to shareholder inactivity or reluctance to accept the deal before its Aug 16 deadline.

Clock
Stada Board Fears Time Is Running Out For Its Takeover • Source: Shutterstock

Racing against the clock, Stada Arzneimittel AG's executive board has voiced worry that the second takeover offer from two private equity suitors will also fail, leaving the German generics maker without a clear future.

With the deadline for acceptances just days away, Stada's leadership has issued an open letter imploring shareholders not to sit on their hands but to accept the improved €4

More from Deals

More from Business

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By 

The sector is continuing to show resilience despite financial and market challenges.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By 

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.